Your browser doesn't support javascript.
loading
Assessing different measures of population-level vaccine protection using a case-control study.
Ali, Mohammad; You, Young Ae; Kanungo, Suman; Manna, Byomkesh; Deen, Jacqueline L; Lopez, Anna Lena; Wierzba, Thomas F; Bhattacharya, Sujit K; Sur, Dipika; Clemens, John D.
Afiliación
  • Ali M; International Vaccine Institute, Seoul, Republic of Korea; Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. Electronic address: mali25@jhu.edu.
  • You YA; International Vaccine Institute, Seoul, Republic of Korea.
  • Kanungo S; National Institute of Cholera and Enteric Diseases, Kolkata, India.
  • Manna B; National Institute of Cholera and Enteric Diseases, Kolkata, India.
  • Deen JL; Menzies School of Health Research, Casuarina, NT, Australia.
  • Lopez AL; University of the Philippines Manila, National Institutes of Health, Philippines.
  • Wierzba TF; International Vaccine Institute, Seoul, Republic of Korea.
  • Bhattacharya SK; National Institute of Cholera and Enteric Diseases, Kolkata, India.
  • Sur D; National Institute of Cholera and Enteric Diseases, Kolkata, India.
  • Clemens JD; icddr,b, Dhaka, Bangladesh; UCLA Fielding School of Public Health, Los Angeles, USA.
Vaccine ; 33(48): 6878-83, 2015 Nov 27.
Article en En | MEDLINE | ID: mdl-26364121
ABSTRACT

BACKGROUND:

Case-control studies have not been examined for their utility in assessing population-level vaccine protection in individually randomized trials.

METHODS:

We used the data of a randomized, placebo-controlled trial of a cholera vaccine to compare the results of case-control analyses with those of cohort analyses. Cases of cholera were selected from the trial population followed for three years following dosing. For each case, we selected 4 age-matched controls who had not developed cholera. For each case and control, GIS was used to calculate vaccine coverage of individuals in a surrounding "virtual" cluster. Specific selection strategies were used to evaluate the vaccine protective effects.

RESULTS:

66,900 out of 108,389 individuals received two doses of the assigned regimen. For direct protection among subjects in low vaccine coverage clusters, we observed 78% (95% CI 47-91%) protection in a cohort analysis and 84% (95% CI 60-94%) in case-control analysis after adjusting for confounding factors. Using our GIS-based approach, estimated indirect protection was 52% (95% CI 10-74%) in cohort and 76% (95% CI 47-89%) in case control analysis. Estimates of total and overall effectiveness were similar for cohort and case-control analyses.

CONCLUSION:

The findings show that case-control analyses of individually randomized vaccine trials may be used to evaluate direct as well as population-level vaccine protection.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra el Cólera / Ensayos Clínicos Controlados Aleatorios como Asunto / Cólera Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Vaccine Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra el Cólera / Ensayos Clínicos Controlados Aleatorios como Asunto / Cólera Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Vaccine Año: 2015 Tipo del documento: Article